"Step change" Yervoy from BMS not cost effective for NICE: may need biomarker test
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, has recognised Bristol-Myers Squibb's Yervoy (ipilimumab) as a "step change" in the treatment of advanced melanoma, according to draft guidance published on 14 October. Despite this, Yervoy would not be a cost-effective use of NHS resources due to uncertainty over its long-term benefits and, in the absence of a biomarker, the patient populations it could help, says the institute.
You may also be interested in...
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.